Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma Ltd. (NYSE:CANF) announced that its study on the treatment of pancreatic carcinoma with Namodenoson has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer. The study showed significant growth inhibition in pancreatic carcinoma patient cells treated with Namodenoson. Can-Fite is planning to submit an exploratory Phase II protocol for approval in Israel and the U.S.
September 27, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite's study on Namodenoson's effect on pancreatic carcinoma has been recognized by AACR, which could boost investor confidence in the company's research capabilities and potential for future success.
The recognition of Can-Fite's study by AACR, a reputable cancer research association, validates the company's research and could potentially attract more investors. The company's plan to submit a Phase II protocol for approval also indicates progress in its research, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100